The ACR applauds the FTC’s recent ban on most noncompete agreements. The ruling is a step in the right direction toward a more competitive market for healthcare workers and their services.
A survey in June, led by the AMA but endorsed by the ACR, will collect data on practice costs and hours of patient care. Practices selected to participate will be contacted via email and U.S. Postal Service, and are encouraged to respond.
Three commercial health insurance payers have increased reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
As of April 1, HCPCS codes for methylprednisolone have changed. The ACR is working with the CMS to determine how rheumatologists should bill Medicare corrrectly.
As ACR leaders and volunteers visit Capitol Hill to advocate for stabilizing Medicare physician payment rates, you can join the effort from anywhere. Send your lawmakers a message today through the Legislative Action Center.
At this year’s Hill Day, attendees will receive in-depth training on Medicare reimbursement and hear from Rep. Larry Bucshon, MD, (R-Ind.) about his perspective on the issue as a physician in Congress.
On May 7, ACR leaders from the Board of Directors, committees and more will to go to Capitol Hill and ask lawmakers to support legislation that would stabilize Medicare reimbursement for physicians.
The Consolidated Appropriations Act, 2024 increased the Medicare conversion factor by 1.68% effective March 9, bringing it to $33.2875 for March 9–Dec. 31, 2024.
On April 1, UnitedHealthcare updated reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
The ACR joined with 52 organizations in thanking House and Senate leaders for introducing the Healthcare Workforce Resilience Act, which would support employment-based visas for international physicians and nurses.